Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 14/20 | 0.63 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.63 |
| ▸ | EIF4E | P06730 | 1/20 | 0.35 |
| ▸ | MPL | P40238 | 4/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18786615 | 0.78 | MKNK1 (1.00) | MKNK1MKNK2EIF4E | |
| SCHEMBL18786948 | 0.77 | MKNK1 (0.69) | MKNK1MKNK2EIF4EMPL | |
| SCHEMBL18786959 | 0.75 | MKNK1 (1.00) | MKNK1MKNK2EIF4E | |
| SCHEMBL18786970 | 0.73 | MKNK1 (1.00) | MKNK1MKNK2EIF4E | |
| SCHEMBL18786855 | 0.71 | PARP10 (0.38) | — | |
| SCHEMBL18786706 | 0.70 | MKNK1 (1.00) | MKNK1MKNK2EIF4E | |
| SCHEMBL18786614 | 0.69 | MKNK1 (1.00) | MKNK1MKNK2EIF4E | |
| SCHEMBL18786755 | 0.69 | MKNK1 (0.49) | MKNK1MKNK2MPL | |
| SCHEMBL18786719 | 0.69 | MKNK1 (1.00) | MKNK1MKNK2EIF4E | |
| SCHEMBL18786803 | 0.69 | MKNK1 (0.58) | MKNK1MKNK2EIF4EMPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190152988-A1 | ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2 | EFFECTOR THERAPEUTICS, INC. (JP) | 2019-05-23 | — | — | US | disclosed |
| US-20190152988-A1 | ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2 | EFFECTOR THERAPEUTICS, INC. (JP) | 2019-05-23 | — | — | US | disclosed |
| US-10112955-B2 | Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of Mnk1 and Mnk2 | EFFECTOR THERAPEUTICS, INC. (US) | 2018-10-30 | — | — | US | disclosed |
| CN-108602805-A | Isoindoline, azaisoindoline, indenone and the dihydro azepine indone inhibitor of MNK1 and MNK2 | 效应治疗股份有限公司 | 2018-09-28 | — | — | CN | disclosed |
| EP-3368530-A1 | ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2 | Effector Therapeutics Inc. (US) | 2018-09-05 | — | — | EP | disclosed |
| US-20170121346-A1 | ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2 | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-05-04 | — | — | US | disclosed |
| US-20170121346-A1 | ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2 | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-05-04 | — | — | US | disclosed |
| US-20170121346-A1 | ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2 | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-05-04 | — | — | US | disclosed |
| WO-2017075394-A1 | ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2 | EFFECTOR THERAPEUTICS, INC. (US) | 2017-05-04 | — | — | WO | disclosed |
| WO-2017075394-A1 | ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2 | EFFECTOR THERAPEUTICS, INC. (US) | 2017-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10112955-B2 | Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of Mnk1 and Mnk2 | NEK9, NEK2, NEK3 | MKNK1 33/4885MKNK2 23/4885EIF4E 2340/4885 |
| US-20190152988-A1 | ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2 | NEK9, NEK2, NEK3 | MKNK1 33/4885MKNK2 23/4885EIF4E 2340/4885 |
| US-20170121346-A1 | ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2 | NEK9, NEK2, NEK3 | MKNK1 33/4885MKNK2 23/4885EIF4E 2340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.